IASO Bio's FUCASO Shows Promising Real-World Data for Multiple Myeloma Treatment

Major Breakthrough in Multiple Myeloma Treatment

IASO Biotechnology, often referred to as IASO Bio, presented compelling real-world data for its innovative CAR-T therapy product, FUCASO (equecabtagene autoleucel injection), during the 2026 International Myeloma Society (IMS) Annual Meeting. This data stems from a comprehensive study of 281 patients in China who were grappling with heavily pretreated relapsed or refractory plasma cell neoplasms, laying a strong foundation for FUCASO's efficacy and safety.

A Deep Dive into the Study

The study, which included patients from various medical centers across China, revealed astounding results. The participants had a median age of 61 years, with many having previously undergone multiple treatment lines—up to 12 lines in some cases. Notably, 84% had received anti-CD38 therapy beforehand, and almost half had undergone autologous stem cell transplantation. This demographic profile marks them as a particularly high-risk group, further showcasing the significance of the findings.

Key Findings from FUCASO's Real-World Usage

The results were indeed remarkable: the objective response rate (ORR) achieved an impressive 95.9%, while the complete response (CR) or stringent complete response (sCR) rate soared to 77.2%. The depth of response was just as remarkable, with a staggering 94.1% of patients achieving minimal residual disease (MRD) negativity. These figures indicate not only the efficacy of FUCASO in delivering profound responses but also hint at its potential durability in patients, with a 12-month progression-free survival (PFS) rate of 71.5% and an overall survival (OS) rate of 87.8%.

Validation in High-Risk Populations

One of the focal points of the study was the efficacy of FUCASO across various high-risk subgroups. For instance, patients aged over 70 and those with prior exposure to anti-CD38 therapy maintained similar response rates to the overall cohort, suggesting that FUCASO's efficacy is consistent, regardless of age or previous treatment history. Furthermore, high-risk patients still demonstrated effective outcomes, which was further validated by FUCASO’s safety profile.

Navigating Safety Challenges

While the results from the real-world study are overwhelmingly positive, they also highlight the importance of safety management in treatment plans. The incidence of any-grade cytokine release syndrome (CRS) was reported at 88.2%, but only 3.8% qualified as grade 3 or worse, indicating that while risks exist, they are largely manageable. The study provides a roadmap for healthcare providers emphasizing that enhanced safety protocols are particularly vital for high-risk patients.

Conclusion: A Bright Future for CAR-T Therapies

The findings shared by Professor Jin Lu from Peking University People's Hospital indicate that FUCASO has the potential to be a game-changer in the treatment landscape for multiple myeloma. Even when confronted with more challenging patient profiles, FUCASO has showcased a promising efficacy that could redefine how clinicians approach such high-risk cases. This real-world data not only validates FUCASO’s pivotal registration study results but also highlights its broad applicability in real-world clinical practice. The journey for FUCASO is just beginning, and the medical community is certainly watching its progress with keen interest.

As the biopharmaceutical landscape continues to evolve, FUCASO's success may inevitably usher in a new era of treatment possibilities for those battling blood cancers.